| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-09-03 | Horizon Discovery (UK) Sigma-Aldrich (USA) | CompoZr ® zinc finger nuclease (ZFN) technology | licensing |
Technology - Services | Licensing agreement | |
| 2013-09-03 | Evercyte (Austria) Vela Labs (Austria) | immortalized target cells for the characterization of biosimilars | commercialisation |
Technology - Services | Commercialisation agreement | |
| 2013-09-03 | Biofocus, a Galapagos Company (UK - Belgium) Aviva Investors (UK) | Services contract | ||||
| 2013-09-03 | Diaxonhit (France) Boehringer Ingelheim (Germany) | novel epitope targets in oncology | R&D |
Technology - Services - Cancer - Oncology | R&D agreement | |
| 2013-09-02 | Selcia (UK) Cantab (UK) | improved antibiotics based on the polymyxin nucleus. | multidrug resistant Gram-negative bacterial infections | collaboration |
Infectious diseases | Collaboration agreement |
| 2013-09-02 | Kymab (UK) | nomination |
Nomination | |||
| 2013-08-30 | OncoDNA (Belgium) Integrated BioBank of Luxembourg - IBBL (Luxembourg) | OncoDEEP DX cancer panel | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2013-08-29 | Zealand Pharma (Denmark) Eli Lilly (USA) | peptide therapeutics | type 2 diabetes, obesity | R&D |
Metabolic diseases | R&D agreement |
| 2013-08-28 | Novabiotics (UK) Taro Pharmaceutical (USA) | Novexatin® | fungal nail infections (onychomycosis) | licensing |
Infectious diseases | Licensing agreement |
| 2013-08-23 | Shire (UK) Santaris Pharma (Denmark) | LNA drug platform | Rare diseases - Genetic diseases | Development agreement | ||
| 2013-08-23 | Okapi Sciences (Belgium) Novartis (Switzerland) | antiviral treatment for cats | development |
Veterinary medicine | Development agreement | |
| 2013-08-20 | Servier (France) Macrogenics (USA - MD) | enoblituzumab (MGA271) | solid tumors | licensing development commercialisation |
Cancer- Oncology | Licensing agreement |
| 2013-08-19 | Sirona Biochem (Canada) Wanbang Pharma (China) | SGLT (Sodium-dependent glucose cotransporter) 2 Inhibitor | licensing |
Licensing agreement | ||
| 2013-08-12 | Duke University (USA) - the Howard Hughes Medical Institute (USA) - Lexicon Pharmaceuticals (USA) - Nuevolution (Denmark) | biological mechanism of action of a specified GPCR drug target | R&D |
Technology - Services | R&D agreement | |
| 2013-08-07 | Lonza (Switzerland) Sorrento Therapeutics (USA) | GS Xceed™ Gene Expression System | licensing |
Technology - Services - Cancer - Oncology - Inflammatory diseases - Infectious diseases | Licensing agreement | |
| 2013-08-06 | Medigene (Germany) Difa Cooper (Italy - Spain) | Veregen® ointment (made from the extract of green tea leaves - catechins) | genital warts | licensing |
Infectious diseases - Gynecology - Women's health | Licensing agreement |
| 2013-08-06 | Novartis (Switzerland) Ensemble Therapeutics (USA) | oral Interleukin-17 inhibitor program | IL-17-mediated diseases | R&D |
Autoimmune diseases – Inflammatory diseases | R&D agreement |
| 2013-08-06 | arGEN-X (The Netherlands - Belgium) undisclosed partner | antibody half-life extension technology NHance™ | licensing | |||
| 2013-08-06 | Oncobiologics (USA - NY) inVentiv Health (USA - NJ) | biosimilar versions of Humira®, Rituxan®, Avastin®, and Herceptin® | collaboration development |
Cancer - Oncology - Autoimmune diseases | Collaboration agreement | |
| 2013-08-05 | Roche (Switzerland) The Medicines Patent Pool | Valcyte® (valganciclovir) | cytomegalovirus (CMV) infections | supply | Infectious diseases |
